Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells

Acta Pharmacologica Sinica

Volumn 28, Issue 1, 2007, Pages 105-110

  Zhang, Kun Zhong ^a   Xu, Jian Hua ^a   Huang, Xiu Wang ^a   Wu, Li Xian ^a   Su, Yu ^a   Chen, Yuan Zhong ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Institute OfHematology   (China)

Author keywords

abl genes; Antisense oligonucleotides; bcr abl fusion proteins; Chronic myelogenous leukemia; Combination drug therapy; Curcumin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BCR ABL PROTEIN; CURCUMIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); DOWN REGULATION; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

EID: 33845999546     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00471.x     Document Type: Article

References (19)

1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-4.
2. Heisterkamp N, Stam K, Groffen J, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph1 translocation. Nature 1985; 315: 758-61.
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
4. Warmuth M, Danhauser-Riedl S, Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 1999; 78: 49-64.
5. Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 2005; 105: 1750-8.
6. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, et al. Cotreatment with STI-571 Enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001; 7: 350-7.
7. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogeous leukemia. Exp Hematol 2001; 29: 543-56.
8. Rapozzi V, Cogoi S, Spessotto P, Risso A, Bonora GM, Quadrifoglio F, et al. Antigene effect in K562 cells of a PEG-conjugated triplexforming oligonucleotide targeted to the bcr/abl oncogene. Biochemistry 2002; 41: 502-10.
9. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcuma: preclinical and clinical studies. Anticancer Res 2003; 23: 363-98.
10. bcr/abl initiated Ras signal transduction pathway. Acta Pharmacol Sin 2003; 24: 1155-60.
11. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-47.
12. bcr/abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11: 355-60.
13. Bhatia R, Vertaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998; 91: 3414-22.
14. Chen LJ, Shen RL, Wang CY, Zhu GR. Ara-C induced apoptosis of HL-60 by AO/EB fluorescent staining. Chin J Hematol 1998; 19: 41-2.
15. Jin ZJ. Additionin drug combination. Acta Pharmacol Sin 1980; 1: 70-6.
16. Clark RE. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 2000; 14: 347-55.
17. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun 1996; 226: 1-7.
18. Sokoloski JA, Shyam K, Sartorelli AC. Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D3. Oncol Res 1997; 9: 31-9.
19. bcr/abl protein in human chronic myelogenous leukemia K562 cells. FASEB J 2000; 14: 1516-9.